Active trials
Read more about the active trials that MedVadis Research is involved with. Contact us anytime if you would like to volunteer or have any questions.
Adult Migraine
Study ID 273
SPRINT® Peripheral Nerve Stimulation for the Treatment of Head Pain
Treatment of Head Pain With the SPRINT® Peripheral Nerve Stimulation (PNS) System
Medical Conditions:
Cervicogenic Headache | Occipital Neuralgia
Related Conditions: Cervicogenic Headache | Occipital Neuralgia
Sex/Gender: All
Age: 21+
Enrolling now!
Study ID ABC
Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention
This Phase 2 Extension trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll approximately 666 patients across approximately 65 sites in the United States, Canada and Australia from the Phase 2 trial. Study subjects will be divided evenly across a low dose group and a high dose group. All patients will receive four treatment cycles of ABP-450 utilizing the Company's novel injection paradigm.
Medical Conditions:
Migraine
Related Conditions: Migraine
Sex/Gender: All
Age: 18+
Enrolling now!
ALS
Study ID 265
A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
Medical Conditions:
Age-Related Macular Degeneration | Allergies | Alpha-Gal Syndrome | Alzheimer Disease
Related Conditions: Age-Related Macular Degeneration | Allergies | Alpha-Gal Syndrome | Alzheimer Disease
Sex/Gender: All
Age: 18-85yrs
Enrolling now!
Study ID 259
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease (REGEN-BRAIN©)
Safety and Efficacy of Allopregnanolone (Allo) as a Regenerative Therapeutic for Alzheimer's Disease: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Clinical Trial
Medical Conditions:
Alzheimer Dimentia | Late Onset Alzheimer's Disease | Neurodegenerative Disease
Related Conditions: Alzheimer Dimentia | Late Onset Alzheimer's Disease | Neurodegenerative Disease
Sex/Gender: All
Age: 55-80yrs
Enrolling now!
Alzheimer’s Disease
Study ID 267
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline
Medical Conditions:
Alzheimer's Disease
Related Conditions: Alzheimer's Disease
Sex/Gender: All
Age: 55-80yrs
Enrolling now!
Chronic Knee Pain
Study ID 501
Placeholder Chronic Knee Pain to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Placeholder Chronic Knee Pain unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam eaque ipsa, quae ab
Medical Conditions:
Chronic Knee Pain
Related Conditions: Chronic Knee Pain
Sex/Gender: Female
Age: 18+
Enrolling now!
Chronic Low Back Pain
Study ID 523
Chronic Low Back Pain Placeholder for Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Chronic Low Back Pain Placeholder testing an thing rapid these after going drawn or. Timed she his law the spoil round defer. In surprise concerns informed betrayed he learning is ye. Ignorant formerly so ye blessing. He as spoke avoid given downs money on we.
Medical Conditions:
Chronic Low Back Pain
Related Conditions: Chronic Low Back Pain
Sex/Gender: Male
Age: 34+
Enrolling now!
Diabetic Neuropathy
Study ID 295
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender: All
Age: 18-80yrs
Enrolling now!
Study ID 268
A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain (NEPTUNE-17)
This is a multicenter randomized, double-blind, placebo-controlled phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics, and target engagement of GSK3858279 in adult participants with chronic Diabetic Peripheral Neuropathic Pain (DPNP). The primary objective of the study is to assess the efficacy of GSK3858279 in participants with DPNP who have been unable to sufficiently manage their pain.
Medical Conditions:
Diabetic Neuropathy
Related Conditions: Diabetic Neuropathy
Sex/Gender: All
Age: 18-75yrs
Enrolling now!
Obesity
Study ID 299
Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide once weekly in participants who have obesity or overweight and chronic low back pain (TRIUMPH-7)
Medical Conditions:
Obesity
Related Conditions: Obesity
Sex/Gender: All
Age: All
Enrolling now!
Study ID 279
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2)
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Medical Conditions:
Obesity | Overweight | Type 2 Diabetes | Obstructive Sleep Apnea
Related Conditions: Obesity | Overweight | Type 2 Diabetes | Obstructive Sleep Apnea
Sex/Gender: All
Age: 18+
Enrolling now!
Pediatric Migraine
Study ID 249
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolescents (≥ 6 to < 18 years of age).
Medical Conditions:
Acute Treatment of Migraine
Related Conditions: Acute Treatment of Migraine
Sex/Gender: All
Age: 6-17yrs
Enrolling now!
Study ID 242
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Medical Conditions:
Migraine
Related Conditions: Migraine
Sex/Gender: All
Age: 6-17yrs
Enrolling now!